SCHEMBL4891075

SCHEMBL4891075

Nc1ccc(Oc2ccnc(Nc3ccccc3)n2)c(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 14/20 0.57
KDR P35968 13/20 0.57
PLK4 O00444 2/20 0.46
AURKA O14965 3/20 0.45
IKBKB O14920 2/20 0.44
PDPK1 O15530 2/20 0.44
CDK1 P06493 2/20 0.44
LYN P07948 2/20 0.44
FGFR1 P11362 2/20 0.44
FGFR3 P22607 2/20 0.44
RPS6KB1 P23443 2/20 0.44
CDK2 P24941 2/20 0.44
MARK3 P27448 2/20 0.44
BLK P51451 2/20 0.44
RPS6KA3 P51812 2/20 0.44
ERBB4 Q15303 2/20 0.44
MARK2 Q7KZI7 2/20 0.44
PLK3 Q9H4B4 2/20 0.44
JAK2 O60674 1/20 0.44
PRKD3 O94806 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1136988 0.90 MET (0.57) METKDRNPC1MAPTMAPK1
SCHEMBL4730654 0.80 MET (0.70) METKDRJAK2JAK3
SCHEMBL14836435 0.78 IKBKB (0.48) METKDRPLK4AURKAIKBKB
SCHEMBL16617012 0.77 AURKA (0.49) METKDRPLK4AURKAIKBKB
SCHEMBL4733743 0.77 RAF1 (0.54) METKDRNPC1RAB9A
SCHEMBL4731957 0.77 GCK (0.46) METKDRGSK3A
SCHEMBL4730251 0.76 MET (0.44) METMAP4K4
SCHEMBL2763172 0.75 MET (0.44) METKDRGSK3A
SCHEMBL24741603 0.73 MEN1 (0.54) MAP4K4SYKNPC1RAB9A
SCHEMBL30108336 0.73 MEN1 (0.54) MAP4K4SYKNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF ABL1, MAP3K20, MAP3K1 MET 545/4885KDR 746/4885PLK4 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.